Stock Market - ACB |
- ACB
- $PRQR - ProQR - Great Pipeline and Catalysts for 2019
- Today's Pre-Market News [Tuesday, March 5th, 2019]
- $PSIQ 153 page filing just filed with SEC Edgar on their OTCQB uplisting. Looks like its a go
- The extraordinary rally in the first two months of 2019 is tough to gauge because earnings estimates crashed in January and most economic readings haven’t been great.
- ACB & Goodwill habits -
- Is it viable to drop out and become a full time trader
- Shorting Barnes and Noble Upcoming EPS Announcement
- Opening a Stocks & Shares ISA, should I choose my own investments, use one of the pre-made portfolios, or a mix of both?
- Need rundown of pharma/biotech space: looking for r&d/medical breakthrough heavy companies
- Johnson and Johnson Long
- Significant rise strategy?
- Ladybaybee stock picks 2019-03-05
- Thoughts on Quinstreet?
- $GBHL News out "Global Entertainment Holdings, Inc. (OTC:GBHL) Seeks Redemption On Its Flag Ship App"
- recommend good sites with graphs/charts?
- Anyone know what happened to the Buzz Index? $BUZ
- US Cannabis Company Shows Off Product Line-Up At Trade Show As They Prepare To Uplist To Higher Exchange.
- Tencent jump, any news?
- anyone looking to buy target this morning?
- MCX Intra-day Levels Tips
| Posted: 05 Mar 2019 11:59 AM PST Someone gave this stock a target price of $14 Canadian and many sources are reporting it as $14 US! $14 Canadian is like $10.50 US. [link] [comments]  |
| $PRQR - ProQR - Great Pipeline and Catalysts for 2019 Posted: 05 Mar 2019 03:08 PM PST Overview(I bought in Friday at 13.80) ProQR is one of the many companies focusing their efforts on developing treatments and new medicines for rare disease that are in dire need of therapeutic options through developing RNA therapies to address genetic diseases. ProQR has a unique story where the company was founded in 2012 by CEO Daniel de Boer who was struck with the diagnosis that his newborn son had cystic fibrosis. Fueled by the desire to not only help his own family, but other patients in need of serious treatment, the genesis of ProQR came about with the help of co-founders Dinko Valerio, Gerard Platenburg, and Henri Termeer. With an experienced executive and leadership team, this company shows great promise for long-term success. Boer has a history of entrepreneurship, having been founder and CEO of RNA Systems, PC Basic and Running IT while also being a co-founder of Amylon Therapeutics, leaving him no stranger to the biotechnology industry. Having a team around him that consisted of the Alison Lawton and his three co-founders, all of which had experience as CEO's of their own pharmaceutical and biotechnology companies. Backing this extensive leadership team is an extensive team on the scientific advisory board of prestigious PhD's and MD's. ProQR has a large umbrella with many different RNA therapy treatments being developed, a majority still in their infancy under the Discovery and Preclinical Development phases. This umbrella encompasses Ophthalmology with 8 different candidates, Dystrophic Epidermolysis Bullosa with 3 candidates, Cystic Fibrosis with 4 candidates, as well as 3 other drug candidates that the company partially owns in conjunction with partners. 18 different drug candidates is quite an extensive list, even with the research compacted into 3 diseases. It appears the company may be throwing as many darts at the board as they can and hoping a few stick, but is that truly the case? Recently announced, the company proposed its "ProQR Vision 2023" strategy, focusing on the commercialization of its drug candidates. The company expects that by 2023, it will have a minimum of two commercial products, at least three late-stage development candidates, and seven early-stage programs in the pipeline. This will all run in conjunction with expanding their RNA platform capabilities to expand into additional therapeutic areas as well as branch away from strictly rare diseases. According to ProQR, the company has several key deliverables for this vision:
Ophthalmology For those who don't know, Ophthalmology is the field of medicine and therapy that deals with the eye. Mentioned previously, ProQR is developing 8 different drug candidates that revolve around this space, notably for the treatment of Usher Syndrome, Stargardt's Disease, Leber's Congenital Amaurosis 10, Autosomal Dominant Retinitis Pigmentosa, and Fuchs Endothelial Corneal Dystrophy. With nearly all candidates in Discovery, Preclinical Development, or just entering Proof of Concept Trials, ProQR does have one late stage development candidate Sepofarsen (QR-110) which it is expected to start its Phase II/III Pivotal Trial in the first half of 2019.
Cystic Fibrosis Hitting close to home, the CEO of ProQR is all too familiar with Cystic Fibrosis (CF) after his son was diagnoses shortly after birth. CF is a genetic disease affecting more than 75,000 people worldwide where the affected have viscous mucus accumulating in their organs, clogging tubes and organs and essentially shutting down vital processes within the body. One of the most common issues is the mucus accumulating in the lungs, creating an ideal environment for bacteria which can't be cleared from the lungs from coughing, leading to inflammation and regular infection. Lung failure is the most common fatal result of this disease, with patients lasting an average of 30 years and despite the wide treatment market available, there are limited options on treating the underlying genetic mutations and create a void of unmet medical needs.
Dystrophic Epidermolysis Bullosa Epidermolysis Bullosa (EB) is a genetic skin disease and Dystrophic Epidermolysis Bullosa (DEB) is the most severe form of the condition. DEB causes blistering of the skin and mucosal membranes that line structures in the body such as the mouth and esophagus. Resulting in fragile skin, there is a week connection between the dermis and epidermis of the skin, causing constant pain. DEB is the result of mutation in the COL7A1 gene responsible for forming collagen type VII protein forming anchoring fibrils that bind the two layers of skin together. Like a majority of the genetic diseases that ProQR works with, there is no treatment for the underlying cause of DEB, only palliative treatments for wound care and pain management.
Partially Owned Programs In conjunction with the current trials and research the company is taking on through their own R&D, the company is also partnering with outside companies Galapagos and Amylon Therapeutics to develop additional novel therapies for rare and currently non-treatable diseases such as Fibrosis and CNS diseases. Upcoming Data and FocusQR-313 is the short term catalyst amongst many that ProQR has in their pipeline. The company is expected to present Phase I/II interim data in the first quarter of 2019. With March newly here, the company is approaching the timeline that they set out. QR-313 is one of their flagship drug candidates that is an RNA-based oligonucleotide designed to address the underlying cause of dystrophic epidermolysis bullosa (DEB) due to mutations in exon 73 of the COL7A1 gene. Currently, the clinical development of QR-313 is supported with funding from EB Research Partnership and EB medical Research Foundation. QR-313 has been granted orphan drug designation in the United States and the European Union, from which ProQR received $5 million in funding to further their research and clinical development. DEB leads to a limited life expectancy and blistering of the skin starting at birth.QR-313 as a topical application not only provides the hope that there is a viable treatment option for patients, but also would allow an easy and convenient application that can be done at home without physician supervision. This compound is currently in the Phase I/II "safety and efficacy study" which the company dubbed WINGS. The name of the study derives from the idea that children with DEB have very fragile skin comparable to that of a butterfly's wings. WINGS is an ongoing international Phase 1/2, double-blind, randomized, intra-subject placebo controlled clinical trial of QR-313 in patients with (recessive) RDEB due to mutations in exon 73 of the COL7A1 gene. 8 patients will be included in WINGS and during the study, QR-313 or placebo formulated in a gel, will be topically applied to a patient's wounds two to three times a week for up to four weeks with an eight-week follow-up period. The Company's primary objectives of WINGS are to test whether QR-313 is safe and tolerated (safety and efficacy study) and to evaluate proof of mechanism by testing, at a molecular level, whether QR-313 actually induces the exon skipping of exon 73 from COL7A1 mRNA and will be assessed by polymerase chain reaction. Secondary objectives are to test the effects on wound healing, skin strength, the presence of collagen type VII protein and anchoring fibrils in the skin as well as systemic distribution of QR-313 after topical administration. Following strong preclinical proof of concept, topical formulation, FDA and EMA orphan drug designation, the company is initiating the clinical trials with full results expected from Phase I/II later in 2019 and interim results in Q1 2019. After initial screening in QR-313 in vitro evolutional of the compound, a single stranded fully phosphorothioated and 2'O-methylated AON, composed of 21 bases was selected to the target sequence which is optimized for length, sequence, lack of immunogenicity and optimal manufacturability. The company utilized the study to assess exon skip efficacy in multiple cell types, especially when administered through topical gel formulation. In vitro transfection of cell cultures Exon skip efficacy of QR-313 was assessed in human primary fibroblasts (HPF), recessive dystrophic epidermolysis bullosa (RDEB) fibroblasts with a mutation in exon 73, and mutated HaCats. Cells were transfected with 3.12- 200 nM QR-313 with polyethylenimine (maxPEI) and subsequently the RNA was isolated and cDNA produced and visually analyzed to estimate skip efficiency through PCR and Bioanalyzers. Immunofluorescent staining of C7 WT fibroblasts or RDEB fibroblasts were plated and subsequently transfected with QR-313 as described above. 72 hours after transfection, cells were fixed with 4% formaldehyde, blocked and stained with a polyclonal Anti-Collagen VII antibody. Exon skip measurements in human skin equivalents (HSEs) composed of both a dermal layer containing fibroblasts in a collagen matrix and an epidermal layer containing keratinocytes were created. The HSEs were cultured on filters at the air-liquid interface for 14 days to induce differentiation of the epidermis and form a stratum corneum. Subsequently, QR-313 formulated in a hydrogel was applied onto the wounded area. The results of this in vitro study produced in the first 24 hours with 25 nM of QR-313 a median skip efficacy measured by PCR of 74% in HPF and 86% in PF, this exon exclusion efficacy is further elevated to a median exon skip of 82% and 87% respectively when the cells were treated with higher concentrations of QR313. After 48 hours the exon 73 exclusion efficacy is further elevated to 100% for all tested concentrations in PF compared to 84% exon exclusion in HPFs treated with 200 nM QR-313. Using CRIPR, a cell line was created by introducing a homozygous single G deletion in exon 73 of COL7A1, this HaCat cell-line and was assessed for the exon skip efficacy of QR-313 24 hours after transfection at a dose range of 3,125-100 nM QR-313. Results demonstrate that QR-313 efficiently excluded exon 73 from the COL7A1 mRNA cell lines, with skip efficiencies of >50% when the cells were transfected with 25 nM or higher concentrations of QR-313. The treated cells also showed normal signs of expression of C7 protein when transfected with QR-313, effectively proving the same functionality as healthy HPF. To assess the efficacy of QR-313 when applied onto HSEs, part of the epidermis was removed to mimic wounded skin before QR-313 was topically. Either 10, 100 or 1000 µg of QR-313 in 200 mg of hydrogel was applied to a wound of 0.8 cm by 2.2 cm. 24 or 48 hours after application the dermis and epidermis were analyzed separately for exon 73 skip. It was observed that with the highest dose QR-313 after 48 hours of incubation all HSEs demonstrated exon skip after 48 hours. The Company concluded that QR-313 is very efficient in the exclusion of exon 73 from the COL7A1 mRNA in fibroblasts of a patient with a mutation in exon 73. In addition, transfection with QR-313 leads to an increase in C7 protein expression in the patient fibroblasts. Moreover, hydrogel-formulated QR-313 is active in inducing exon 73 skip in COL7A1 in wounded HSEs, which mimics the situation in patient skin. The company also has research which demonstrates that Cy5-labeled QR-313 delivery in vitro, ex vivo, and in vivo models are successful in wounded skin treatment but not with intact skin. This makes the delivery method of the hydrogel formulation being pursued for QR-313 a viable option for wound treatment in patients. The Phase I/II trial in DEB patients will seek several endpoints. The primary endpoint being safety, tolerability, and the demonstration of exon skipping in the group receiving the topical treatment. Secondary endpoints will be C7 protein detection, anchoring fibrils being formulated, wound healing, and length of time it takes for patients to re-blister. The interim data will provide a proof of concept that exon skipping, C7 protein detection, and anchoring fibrils are all being demonstrated in patients when reported in Q1 2019. Full data on all patients will be available later in 2019. There is a potential for extension of the study in the same patients to test various dosing regimens and administration routes. There are approximately 2,000 patients in the U.S. and Europe that have the genetic mutation on the COL7A1 gene on exon 73, making the market rather small. But there is a market as demonstrated by the $5 million in funding by the EB organizations. Recent EventsIn December, following the recent success of the company, ProQR Therapeutics was added to the NASDAQ Biotechnology Index (NASDAQ: NBI). FinancialsThe end of 2018 showed that ProQR held cash and cash equivalents of €105.6 million, up more than double what the company held compared to the end of Q4 in 2017. This influx of cash was driven by the recent public offering in September which netted €84.2 million. In the fourth quarter, the company's operating expenses came to €11.3 million and reached €30.7 for the year in total, with research and development consisting of a majority of the expenses. The company posted a net loss of €13.0 million or €0.33 per diluted share for the fourth quarter and a cumulative €37.1 million or €1.09 per diluted share for the year. The company has a fairly substantial burn rate. With clinical trials moving forward and potential positive interim data for the QR-313 study as well as other studies they have planned data for in 2019, additional trials are going to be conducted, increasing costs. Comparing the operating costs of 2017 and 2018, they were roughly identical with only a minor difference between them, actually showing operating costs decreasing year over year. I believe that it is safe to assume that for 2019, operating costs will continue to stay at around €30 million for the time being, leaving the company a bit of buffer room for growing operations, initiating new trials, and maintaining investor growth without fear of dilution on the horizon. Even with increasing expenses and additional trials being initiated, the company appears to have more than two years of cash and cash equivalents on hand to hold them over without the need to raise additional funding. The company states that it now has a cash runway to lead into 2021. *Epidermolysis Bullosa Market *Epidermolysis Bullosa (EB) is both a clinical and genetic group of inherited blisters which affects over 500,000 individuals globally, with 32% of the EB treatment market stemming from the United States according to Technavio. Due to the genetically heterogeneous nature of this disease, the most promising treatment option lies within gene therapy and treating the underlying genetic mutations causing EB. Low prevalence, lack of industry research and exposure, and no current viable treatment options exist for EB causing this disease to be deemed non-curable and can become a cause of cancer. However, as demand and exposure continue to escalate for this disease, we are seeing an influx of funding into research from the US, Europe, and Asia with the largest push coming from Europe despite Asia having the largest potential market. While Asia will have higher incremental growth than both the US and Europe in this field, ProQR has received the orphan drug designation from the U.S. FDA and European Medicines Agency making these two markets the major focus for the company. The US is expected to dominate the market compared globally but will start to lose market share overall as EU and Asia begin larger pushes into the industry. The global EB market currently sits just north of $1.35 billion in 2018 and is projected to grow at a compound annual growth rate (CAGR) of roughly 5% to approximately $1.65 billion by 2022 according to Technavio. The steady growth of the market is driven by the increasing funds poured into the research industry regarding this disease as current treatment options have severe side effects, do little to treat the underlying issues, and are inadequately effective. Currently, antibiotics account for roughly 43% of the market for therapeutic treatments of EB. With further development into gene therapy, this treatment option is expected to take over the EB market as the dominating therapy. Gene therapy has become of the powerhouses in the biotechnology field, and is projected by many to begin replacing therapeutic options that are currently commonplace. "At present, a few gene therapies are approved globally, these therapies have proven to be highly effective for the treatment of various indications. This resulted in several companies conducting clinical trials using gene therapy for the treatment of epidermolysis bullosa. Majority of these studies are still in the clinical trial phase," says a senior analyst at Technavio. Outside of antibiotics, the segment that will account for the highest market share in the EB therapeutics market due to the recent approvals of broad-spectrum combinational antibiotics for the treatment of hospital infections that are easily developed in patients with epidermolysis bullosa, and gene therapy, analgesics are a common therapy option for EB patients suffering from severe pain. While not directly treating the disease, analgesics improve quality of life for patients but will likely phase out as viable long-term treatment options become approved. Competition There is an extensive list of competition in various stages of development in the Ophthalmology, Dystrophic Epidermolysis Bullosa, and Cystic Fibrosis markets. While many are working on similar conditions, no company is attacking the RNA field in the way that ProQR is. ProQR is focusing on the underlying cause of these genetic mutations and conditions, rather than treating the condition on the surface. Some companies that are in the DEB Market there are:
ReviewProQR has an extensive leadership committee that has demonstrated a track record of success. With several former CEO's holding executive level positions in the company as well as a long list of medical professionals and researchers in the RNA fields, the company has a positive outlook. The company has recently diluted shares through a public offering, raising over $100 million in funding and giving the company a cash runway that will hold them through into 2021. Having recently been added to the Nasdaq Biotechnology Index and obtaining a new Chief Medical Officer, the company is poised to continue its march higher in market cap. The company has several upcoming catalysts in 2019. In January, an agreement was reached with the FDA on the design of the pivotal Phase II/III ILLUMINATE trial which is expected to begin in the first half of 2019. In December 2018, the FDA cleared the IND application for QR-421a for Usher syndrome type 2 and non-syndromic retinitis pigmentosa due to mutations in exon 13 of the USH2A gene. The Phase I/II STELLAR trial is expected to initiate in the first half of 2019, with interim data expected in mid-2019. In October 2018, the company obtained exclusive worldwide rights for QR-1123 from Ionis Pharmaceuticals with first in human Phase I/II clinical trial in adRP patients is expected to start in 2019. The WINGS first clinical trial to evaluate the safety and efficacy of QR-313 in patients that have recessive dystrophic epidermolysis bullosa from mutations in exon 73 of the COL7A1 gene, was initiated in mid-2018 and interim data are expected in Q1 2019 with full results in 2019. Although treating rare diseases, ProQR is excited with the revenue potential from their extensive pipeline. Epidermolysis Bullosa alone affects over 500,000 individuals globally, let alone the other research fields that the company is involved with. With millions of potential patient's worldwide that have no current viable treatment options that treat the underlying causes of these genetic conditions, the potential to obtain massive market share in these spaces is exciting. The company skyrocketed from $7 in September 2018 to over $22 in just a few short days. The share price has had fluctuations over the past few months following the public offering, profit taking, and likely skepticism moving forward with so many clinical trials. However, the current share price around $14 looks like a promising opportunity. Great news seems to move the share price for this company like no other. With the fear of dilution taken out of the equation, interim data and the initiation of clinical trials coming in the first half of 2019 and full data results later in 2019, the company has an excellent timeline of potential great news. While these products have demonstrated their safety and efficacy early on, these early stage studies will likely reinforce that data, providing positive results. I believe that PRQR has great opportunity for success in the next 2 years while they trials are young and they have the cash reserves to burn. While not a short-term play, a long-term entry here will like prove fruitful. I would however be cautious as the trials begin to enter late stage clinical trials and development, despite having orphan status there is not an extensive amount of data available currently and there is a reason that there are no current treatment options that treat the underlying causes of these genetic diseases. They are difficult to work with and this is a newer concept of treatment, leaving concern on TLDRFuck you read my writing. But extensive pipeline. Cash runway to 2021. 3 or 4 trial catalysts in first half of 2019. Share price loves to move on positive news. All early stage trials and safety and efficacy appears to be present for these orphan drug designated candidates which means they will all likely move into late Phase II/III studies. Good entry. [link] [comments]  |
| Today's Pre-Market News [Tuesday, March 5th, 2019] Posted: 05 Mar 2019 05:20 AM PST Good morning traders and investors of the r/StockMarket sub! Welcome to Tuesday! Here are your pre-market news this AM-(CLICK HERE TO VIEW THE FULL SOURCE!)Today's Top Headlines for Tuesday, March 5th, 2019
STOCK FUTURES CURRENTLY:(CLICK HERE FOR STOCK FUTURES CHARTS!)YESTERDAY'S MARKET MAP:(CLICK HERE FOR YESTERDAY'S MARKET MAP!)TODAY'S MARKET MAP:(CLICK HERE FOR TODAY'S MARKET MAP!)YESTERDAY'S S&P SECTORS:(CLICK HERE FOR YESTERDAY'S S&P SECTORS CHART!)TODAY'S S&P SECTORS:(CLICK HERE FOR TODAY'S S&P SECTORS CHART!)TODAY'S ECONOMIC CALENDAR:(CLICK HERE FOR TODAY'S ECONOMIC CALENDAR!)THIS WEEK'S ECONOMIC CALENDAR:(CLICK HERE FOR THIS WEEK'S ECONOMIC CALENDAR!)THIS WEEK'S UPCOMING IPO'S:(CLICK HERE FOR THIS WEEK'S UPCOMING IPO'S!)THIS WEEK'S EARNINGS CALENDAR:($CRM $NIO $TGT $WB $PLUG $KSS $MGIC $YY $CIEN $IPAR $KR $BZUN $OKTA $BCRX $COST $SINA $SESN $DLTR $LUNA $CTRP $ANF$MEET $ACRX $GDP $SPKE $ADMS $URBN $GNC $GMS $BURL $LJPC $BJ $ADUS $THO $VNET $MRVL $GSKY $GAIA $ROST $AEO $TPB) (CLICK HERE FOR THIS WEEK'S EARNINGS CALENDAR!)THIS MORNING'S PRE-MARKET EARNINGS CALENDAR:($NIO $TGT $WB $KSS $CIEN $SINA $GDP $GMS $GSKY $GNC $DOVA $TPB $AFI $JW.A $CMRX $STIM $GNK $OBSV $JASN $ARPO $BEST) (CLICK HERE FOR THIS MORNING'S EARNINGS CALENDAR!)THIS AFTERNOON'S POST-MARKET EARNINGS CALENDAR:() ([CLICK HERE FOR THIS AFTERNOON'S EARNINGS CALENDAR!]())T.B.A. EARNINGS RELEASES BEFORE THE OPEN TODAY:(CLICK HERE FOR THIS MORNING'S EARNINGS RELEASES!)EARNINGS RELEASES AFTER THE CLOSE TODAY:(CLICK HERE FOR THIS AFTERNOON'S EARNINGS RELEASES!)YESTERDAY'S ANALYST UPGRADES/DOWNGRADES:(CLICK HERE FOR YESTERDAY'S UPGRADES/DOWNGRADES LINK #1!)(CLICK HERE FOR YESTERDAY'S UPGRADES/DOWNGRADES LINK #2!)YESTERDAY'S INSIDER TRADING FILINGS:(CLICK HERE FOR YESTERDAY'S INSIDER TRADING FILINGS!)TODAY'S DIVIDEND CALENDAR:(CLICK HERE FOR TODAY'S DIVIDEND CALENDAR!)THIS MORNING'S MOST ACTIVE TRENDING TICKERS:
THIS MORNING'S STOCK NEWS MOVERS:(source: cnbc.com)
FULL DISCLOSURE:
DISCUSS!What is on everyone's radar for today's trading day ahead here at r/StockMarket? I hope you all have an excellent trading day ahead today on this Tuesday, March 5th, 2019! :)[link] [comments]  |
| $PSIQ 153 page filing just filed with SEC Edgar on their OTCQB uplisting. Looks like its a go Posted: 05 Mar 2019 04:04 PM PST |
| Posted: 05 Mar 2019 07:26 PM PST Global manufacturing hit a 32 month low in February as its PMI fell to 50.6. February light vehicle sales were down 2.3% year over year. The economic surprise index is at -43.4 which is the worst reading since mid-2017. CNBC's median tracking estimate for Q1 GDP growth is only 1%. Q1 2019 estimates fell 6.5% which is the biggest decline in the first two months of a quarter since Q1 2016 when estimates fell 8.4%. Energy, materials, and technology saw estimate declines of 32.3%, 15.2%, and 8.2%. Each S&P 500 sector is performing almost exactly the opposite as it did in Q4 2018. The biggest losers have become the biggest winners. [link] [comments]  |
| Posted: 05 Mar 2019 07:56 PM PST I was reading an article on fool.com where it said ACB is buying companies at an avg of 80% goodwill. For ex - recently it bought a company for $2B of which 80% was attributed towards goodwill. What are your thoughts? [link] [comments]  |
| Is it viable to drop out and become a full time trader Posted: 05 Mar 2019 06:56 PM PST So I'm 18 years old and I recently got kicked out of university because I became depressed that I was in a major I couldn't succeed in and I failed miserably. From my earliest memories of school I was always a terrible student because I only excelled in things that I was passionate about. I was convinced that since I couldn't succeed academically there was no way would be successful in life and it drove me into severe depression and I didn't want to continue in life. I did find a passion in trading and I spent most of my time learning everything I could on the market and how to be profitable. I've seen so many people escape 9-5 jobs to full time trade and I was wondering if this could be an option for me. Currently I'm enrolled in community college which is driving me into depression because I just can't be successful in school. Is it viable for me to drop out of community college and spend all the money I had for tuition on a mentor like steven dux and be successful? [link] [comments]  |
| Shorting Barnes and Noble Upcoming EPS Announcement Posted: 05 Mar 2019 09:58 AM PST Hey guys, Im thinking about shorting B&N since no acquisition offers have been made and pop in stock was due to rumors of acquisition it seems. I think they will fall short of EPS announcement this Thursday....thoughts? [link] [comments]  |
| Posted: 05 Mar 2019 02:00 PM PST The title says it all, really. For anyone unfamiliar (as I think ISAs are a UK thing. I'm sure variants exist in most places, but probably under different names and such!), an ISA is an Investment Savings Account where you can invest up to £20k annually without having to pay any kinds of taxes on any investments within that £20k annual limit. Anyway, there are multiple companies that offer ISAs, some of which allow you to use a 'pre-made portfolio' where their own team of specialists invest in a diversified portfolio for you, therefore it's pretty passive on your part. Oftentimes, you can choose which pre-made portfolio you'd prefer (e.g. low risk, moderate risk, high risk). As I'm only 22, I'm much more interested in the high risk options, as I intend to invest long term. From what I've gathered from many of these high risk portfolios, they average between 6-7% returns each year over a number of years. Considering the little effort this requires on my part, and with my relatively low knowledge on stocks, naturally I'm drawn to doing this. The alternative is investing in the stock market myself, I saw a post on here saying that the returns on the S&P 500 are closer to 10% annually which is obviously a decent bit larger than the 6-7% I could get with a pre-made portfolio. So in terms of raw returns, that would obviously be better, however it would presumably require me to learn more about buying, selling, and managing my stocks. Or should I split investments between both? If so, what is a sensible proportional split? I'll explain a bit about my financial situation too. I'm hoping I'll be able to save/invest around £600-£800 a month once I open my ISA. Also, I'm still currently on my graduate job's starting salary, as I only started recently, so the amount I'll be able to put aside into my ISA each month will increase alongside my future pay rises and such. I also plan to reinvent all of my returns, Also, for those of you in the UK who are investing with a ready-made portfolio in your ISAs, if there's any of you out there, which one are you using and would you recommend it? And my final question, for those of you looking for strong long term growth (over at least 10-15 years), what stocks would you folks recommend investing in? I really appreciate any advice you folks could give me! As you can probably tell, I'm nowhere near the level of knowledgeable as some of you guys, so I really mean it! Thank you all for reading :) [link] [comments]  |
| Need rundown of pharma/biotech space: looking for r&d/medical breakthrough heavy companies Posted: 05 Mar 2019 01:15 PM PST It's a very time-consuming area to research so I was hoping someone in the know could lead me in the right direction. Ideally I'm looking for companies that have a model of profiting through development of innovative treatments, and then selling off those assets to put back into research. I'm guessing there are no pure-plays actually fitting that criteria, but just knowing where many companies are on the spectrum of how their model works would be helpful for me (whether they focus on merger&acquisitions, competitive pricing, etc.) [link] [comments]  |
| Posted: 05 Mar 2019 06:04 PM PST |
| Posted: 05 Mar 2019 05:50 AM PST Hi, right now I'm debating about what to do with couple stocks with recent high gains, AYX and QURE I remember Buffett's "be fearful when others are greedy" and I sold AYX at $71, now Im thinking of selling QURE too, and later figure out a re entry when they cool off a little my main TA reference is the RSI, both stocks where in overbought territory, any thoughts? [link] [comments]  |
| Ladybaybee stock picks 2019-03-05 Posted: 05 Mar 2019 08:28 AM PST You can follow my picks on twitter @ladybaybee1 HOW I USE THIS: 1) All the stocks identified in the table are qualified as "BUY" opportunities. 2) I focus in the column "Success Rate(3m)" which shows the precision of the agents in the last 3 calendar months. I personally feel most comfortable with Rates 0.8 or higher. 3) Then, I see the number in "Tx(3m)" which represents the number of transactions that the agents predicted for this stock in the last 3 months. I prefer stocks that have had at least two transactions during this period. 4) Finally, I look at Growth(3m), if the agents have had a considerable growth (>5% in 3 months) then I follow that trade. 5) If a row in the table is colored green then it means that stock has been on the rise today so I purchase it immediately in order to ride the wave up. On the other hand, if the row is colored red, then I wait out until very close to market close to purchase the stock and let the price bottom out before climbing up again tomorrow. 6) After I purchase the stocks, I ALWAYS set a stop loss order at -2.5% from my buying price valid for the day. I think this is good hygiene, no matter how confident I am of my system, I still want to make sure that my losses are capped. I update this stop loss order every day. BACKGROUND I am not a financier or economist. I am electrical engineer with equal passion in artificial intelligence and financial markets. For the past 2 years I have been working on a system that would make short term predictions of stocks. The system is rather complex, I use multiple layers which include: Convolutional Neural Networks, LSTMs and Genetic Algorithms. All bulked together produce an output like in this image. The way to interpret the image is a follows: Symbol and Date columns are self explanatory, Quorum refers to autonomous agents that decide whether to BUY/NOT BUY or SELL/HOLD a stock. Each symbol has 9 agents, and the Quorum column, counts the number of agents that recommend Buy, Selling or Holding the stock. The "Not Owned" column means: if you don't own this stock then you should … The "Owned" column means: if you own this stock you should HOLD or SELL. The column "Growth(1 Year)" refers to what what has been the growth of this system of Agents in the past calendar year. The column "Tx(1Yr)" shows the number of full transactions that these agents recommended in the last calendar year. "Factor" is just the division of Growth divided by Transactions to get the average growth per transaction. Finally "Success Rate" shows how successful these agents have been in their recommendations in the past calendar year, success 1 means 100% successful, 0.5 means 50% successful, and so on. Many people have been curious about the actual process that the system follows, so here it is: for every symbol (600 stocks are analyzed daily), we get the full stock data (open,close,high,low,volume) for the past 4 months. Each stock is associated with another set of "lookalike" stocks as well as major ETF's. This initial dataset is run through a convolutional layer that extracts an undisclosed number of features. These features are then passed onto a recurrent neural network (LSTM) where sequences and patterns are extracted. The LSTM then spits out probabilities for the likelihood that this stock will have a positive, negative and neutral tendency in the next N days. These probabilities are then fed to a genetic evolution system (GES). This system essentially checks the predictions for the past N days and compares them with reality, following that the systems knows which predictions are performing the best. Once the system knows which stocks are being simulated the best, then the system automatically finds which of these best performing stocks have the biggest potential for the next few days. The system does not output explanations, unfortunately us humans are not capable of understanding (or visualizing) a problem of this dimensionality, for example the LSTM part alone works with over 10 million dimensions, not features but dimensions. [link] [comments]  |
| Posted: 05 Mar 2019 08:25 AM PST |
| Posted: 05 Mar 2019 07:31 AM PST |
| recommend good sites with graphs/charts? Posted: 05 Mar 2019 06:57 AM PST trying to see how well amd and intel is doing and which is doing better i assume the easiest simplest way is to look at the market cap, and to see if it's trending up or down looking for good sites that shows the market cap (or w/e data/metric is helpful) of both amd and intel in one graph so can be compared thanks [link] [comments]  |
| Anyone know what happened to the Buzz Index? $BUZ Posted: 05 Mar 2019 06:47 AM PST |
| Posted: 05 Mar 2019 06:31 AM PST
[link] [comments]  |
| Posted: 05 Mar 2019 12:41 AM PST |
| anyone looking to buy target this morning? Posted: 05 Mar 2019 03:17 AM PST |
| Posted: 05 Mar 2019 03:16 AM PST BuY SILVER Above 38150 SL 38050 Tgt 38225 - 38300 - 38400 - 38450 - 38525 - 38550 SeLL SILVER Below 38050 SL 38150 Tgt 37975 - 37900 - 37800 - 37750 - 37675 - 37650 --------------------------------------------------------------------------------------------------------------------------- BuY GOLD Above 32449 SL 32369 Tgt 32509 - 32569 - 32649 - 32689 - 32749 - 32769 SeLL GOLD Below 32369 SL 32449 Tgt 32309 - 32249 - 32169 - 32129 - 32069 - 32049 --------------------------------------------------------------------------------------------------------------------------- BuY CRUDEOIL Above 3999.5 SL 3974.8 Tgt 4013 - 4040 - 4058 - 4076 - 4094 - 4107.5 SeLL CRUDEOIL Below 3974.75 SL 3999.5 Tgt 3977 - 3950 - 3932 - 3914 - 3896 - 3882.5 --------------------------------------------------------------------------------------------------------------------------- BuY LEAD Above 150.1 SL 149.4 Tgt 150.3 - 150.5 - 150.7 - 151.1 - 151.4 - 152 SeLL LEAD Below 149.45 SL 150.1 Tgt 149.2 - 149 - 148.9 - 148.5 - 148.2 - 147.6 --------------------------------------------------------------------------------------------------------------------------- BuY NICKEL Above 951.3 SL 948.3 Tgt 953.9 - 955.2 - 956.5 - 960.4 - 961.7 - 965.6 SeLL NICKEL Below 948.31 SL 951.3 Tgt 946.1 - 944.8 - 943.5 - 939.6 - 938.3 - 934.4 --------------------------------------------------------------------------------------------------------------------------- BuY COPPER Above 463.4 SL 461.4 Tgt 464.4 - 465.4 - 466.4 - 467.4 - 469.9 - 471.4 SeLL COPPER Below 461.4 SL 463.4 Tgt 460.4 - 459.4 - 458.4 - 457.4 - 454.9 - 453.4 --------------------------------------------------------------------------------------------------------------------------- BuY ZINC Above 197.55 SL 196.8 Tgt 197.8 - 198 - 198.1 - 198.5 - 198.8 - 199.4 SeLL ZINC Below 196.8 SL 197.6 Tgt 196.6 - 196.4 - 196.3 - 195.9 - 195.6 - 195 --------------------------------------------------------------------------------------------------------------------------- BuY ALUMINIUM Above 147.4 SL 146.7 Tgt 147.6 - 147.8 - 148 - 148.4 - 148.7 - 149.3 SeLL ALUMINIUM Below 146.75 SL 147.4 Tgt 146.5 - 146.3 - 146.2 - 145.8 - 145.5 - 144.9 --------------------------------------------------------------------------------------------------------------------------- BuY NATURAL GAS Above 203.55 SL 202.9 Tgt 203.8 - 204.1 - 204.5 - 204.9 - 205.4 - 205.8 SeLL NATURAL GAS Below 202.9 SL 203.6 Tgt 202.4 - 202.1 - 201.8 - 201.3 - 200.9 - 200.4 [link] [comments]  |
| You are subscribed to email updates from r/StockMarket - Reddit's front page of the stock market, financial news. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
No comments:
Post a Comment